# Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin

> **NCT05415345** · PHASE4 · UNKNOWN · sponsor: **Xiamen Innovax Biotech Co., Ltd** · enrollment: 480 (estimated)

## Conditions studied

- Human Papilloma Virus Infection Type 16
- Human Papilloma Virus Infection Type 18
- Hepatitis E Virus Infection

## Interventions

- **BIOLOGICAL:** Cecolin
- **BIOLOGICAL:** Hecolin

## Key facts

- **NCT ID:** NCT05415345
- **Lead sponsor:** Xiamen Innovax Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-25
- **Primary completion:** 2022-11-30
- **Final completion:** 2023-06-10
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2022-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05415345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05415345, "Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05415345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*